Clinical Trial Update: ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for ACTOplus Met XR in patients with stage I-IV oral cavity or oropharyngeal cancer undergoing definitive treatment; the study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cavity Squamous Cell Carcinoma
• Oropharyngeal Squamous Cell Carcinoma

Drugs mentioned

• ACTOplus Met XR (metformin/sulfasalazine extended release combination with ACTOplus Met XR formulation)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Oral Cavity Neoplasm, Oropharyngeal Neoplasm | Phase 2 | Status: TERMINATED | Results posted: 2023-03-08